Cremers Cor W R J, O'Connor Alec Fitzgerald, Helms Jan, Roberson Joseph, Clarós Pedro, Frenzel Henning, Profant Milan, Schmerber Sébastien, Streitberger Christian, Baumgartner Wolf-Dieter, Orfila Daniel, Pringle Mike, Cenjor Carlos, Giarbini Nadia, Jiang Dan, Snik Ad F M
Dept. of Otorhinolaryngology, Radboud University Nijmegen Medical Centre, Donders Institute for Cognition, Brain, and Behaviour, Nijmegen, The Netherlands.
Int J Pediatr Otorhinolaryngol. 2010 Nov;74(11):1267-9. doi: 10.1016/j.ijporl.2010.07.028. Epub 2010 Sep 15.
Active middle ear implants augment hearing in patients with sensorineural, conductive, and mixed hearing losses with great success. However, the application of active middle ear implants has been restricted to compromised ears in adults only. Recently, active middle ear implants have been successfully implanted in patients younger than 18 years of age with all types of hearing losses. The Vibrant Soundbridge (VSB) active middle ear implant has been implanted in more than 60 children and adolescents worldwide by the end of 2008. In October 2008, experts from the field with experience in this population met to discuss VSB implantation in patients below the age of 18.
A consensus meeting was organized including a presentation session of cases from worldwide centers and a discussion session in which implantation, precautions, and alternative means of hearing augmentation were discussed. At the end of the meeting, a consensus statement was written by the participating experts. The present consensus paper describes the outcomes and medical/surgical complications: the outcomes are favourable in terms of hearing thresholds, speech intelligibility in quiet and in noise, with a low incidence of intra- and postoperative complications.
Taken together, the VSB offers another viable treatment for children and adolescents with compromised hearing. However, other treatment options should also be taken into consideration. The advantages and disadvantages of all possible treatment options should be weighed against each other in the light of each individual case to provide the best solution; counseling should include a.o. surgical issues and MRI compatibility.
有源中耳植入物在治疗感音神经性、传导性和混合性听力损失患者方面极大地提高了听力，成效显著。然而，有源中耳植入物的应用目前仅限于成年患者的受损耳朵。最近，有源中耳植入物已成功植入18岁以下患有各种听力损失的患者体内。截至2008年底，全球已有60多名儿童和青少年植入了Vibrant Soundbridge（VSB）有源中耳植入物。2008年10月，该领域有此类患者治疗经验的专家齐聚一堂，讨论在18岁以下患者中植入VSB的相关问题。
组织了一次共识会议，包括来自世界各地中心的病例展示环节以及一个讨论环节，在讨论环节中对植入、注意事项和其他听力增强方法进行了讨论。会议结束时，参与会议的专家撰写了一份共识声明。本共识文件描述了治疗结果以及医疗/手术并发症：就听力阈值、安静和嘈杂环境下的言语清晰度而言，治疗结果良好，术中和术后并发症发生率较低。
总体而言，VSB为听力受损的儿童和青少年提供了另一种可行的治疗方法。然而，也应考虑其他治疗选择。应根据每个病例权衡所有可能治疗选择的利弊，以提供最佳解决方案；咨询内容应包括手术问题和MRI兼容性等方面。
